- Home
- NYXH vs TNGX Comparison
NYXH vs TNGX Comparison
Compare NYXH & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYXH
- TNGX
- Stock Information
- Founded
- NYXH 2009
- TNGX 2014
- Country
- NYXH Belgium
- TNGX United States
- Employees
- NYXH N/A
- TNGX N/A
- Industry
- NYXH Medical/Dental Instruments
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- NYXH Health Care
- TNGX Health Care
- Exchange
- NYXH Nasdaq
- TNGX Nasdaq
- Market Cap
- NYXH 394.1M
- TNGX 317.4M
- IPO Year
- NYXH 2021
- TNGX N/A
- Fundamental
- Price
- NYXH $6.06
- TNGX $1.49
- Analyst Decision
- NYXH Strong Buy
- TNGX Strong Buy
- Analyst Count
- NYXH 4
- TNGX 7
- Target Price
- NYXH $14.50
- TNGX $12.33
- AVG Volume (30 Days)
- NYXH 290.0K
- TNGX 726.7K
- Earning Date
- NYXH 05-13-2025
- TNGX 05-07-2025
- Dividend Yield
- NYXH N/A
- TNGX N/A
- EPS Growth
- NYXH N/A
- TNGX N/A
- EPS
- NYXH N/A
- TNGX N/A
- Revenue
- NYXH $4,680,609.00
- TNGX $42,069,000.00
- Revenue This Year
- NYXH $504.18
- TNGX N/A
- Revenue Next Year
- NYXH $149.52
- TNGX N/A
- P/E Ratio
- NYXH N/A
- TNGX N/A
- Revenue Growth
- NYXH 3.98
- TNGX 15.17
- 52 Week Low
- NYXH $5.55
- TNGX $1.11
- 52 Week High
- NYXH $12.21
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- NYXH 31.41
- TNGX 50.69
- Support Level
- NYXH $5.62
- TNGX $1.24
- Resistance Level
- NYXH $6.09
- TNGX $1.44
- Average True Range (ATR)
- NYXH 0.54
- TNGX 0.15
- MACD
- NYXH 0.05
- TNGX 0.06
- Stochastic Oscillator
- NYXH 27.76
- TNGX 80.56
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.